November 12, 2012 15:08
FAS green-lights AFK Sistema bid to buy 100% of VeroPharm, but with terms (Part 2)
MOSCOW. Nov 12 (Interfax) - Russia's Federal Antimonopoly Service (FAS) has approved AFK Sistema's (RTS: AFKS) request for permission to buy 100% of the stock in pharmaceuticals company OJSC VeroPharm (RTS: VRPH), but has attached some terms, a FAS statement says.
The FAS established that VeroPharm has a dominating position on the market for medicines with MNN Gemifloksatsin, and its subsidiary LLC LENS-Pharm with MNN Poliadenilovaya Kislota + Poliuridilovaya Kislota.
The FAS takes the view that the conduct of this deal could lead to a limiting of access to the market for the sale of these medical preparations by independent counteragent VeroPharm and LENS-Pharm. In light of this, the FAS requires of Sistema and VeroPharm to ensure the fulfillment of all contracts for the delivery of all medicines existing on the date the deal is completed.
Before the deal is done, Sistema is to post on its official website the document regulating its commercial policy as regards VeroPharm medical preparations, and announce changes to commercial policy in letter form to the FAS within thirty days.
The parties are not to, from the date the deal is completed, effect any unfounded economic or technological reduction or halt of the production and supply of goods that are still in demand. They are also to announce to the FAS either of such circumstances in letter form within thirty days.
AFK Sistema and VeroPharm are to annually inform the FAS in letter form that they are meeting these conditions.
The parties to the deal are to announce its completion to the anti-monopoly agency within twenty days from the day the deal is wrapped up.
According to DSM Group data, VeroPharm is third in a rating of the largest Russian pharmaceutical companies. Company product is provided by three plants: in Belgorod, Voronezh, and Pokrov. VeroPharm specializes in the production of Rx medical goods, which account for about 70% of its sales revenues.
Pharmacy Chain 36.6 (RTS: APTK) owns 51.8% of the company.
(Our editorial staff can be reached at firstname.lastname@example.org)
December 18, 2017
Japanese Iida Group may increase investment in Russian forestry, homebuilding to $220 mln
Russia alarmed by U.S. attempts to list it among its adversaries - Ryabkov
Daily Headline News for December 18, 2017
Set of measures to support Russian birth rate will cost 530 bln rubles in 3yr period - Topilin
Russia, Syria to create unified operator to work on Syrian phosphate deposit - Rogozin
SISTEMA PLANS TO IMPLEMENT COURT RULING 'IN ACCORDANCE WITH THE LAW' WHILE SIMULTANEOUSLY APPEALING IT - STATEMENT
Russia, U.S. can overcome crisis in relations based on principles of equality, mutual respect - Deputy Foreign Minister Ryabkov
Syria suffered $400 bln damage from war that continued several years - Rogozin citing al-Assad
WASHINGTON'S NOTIFYING MOSCOW OF TERROR ATTACK PREPARATIONS IN ST. PETERSBURG IS ONLY MINOR EXAMPLE OF POTENTIAL OF RUSSIA-U.S. INTERACTION - U.S. AMBASSADOR TO RUSSIA
RUSSIA, SYRIA TO CREATE UNIFIED OPERATOR TO WORK ON SYRIAN PHOSPHATE DEPOSIT - ROGOZIN
Rogozin meets with al-Assad, holds talks with head of Syrian govt during visit to Syria
RUSSIA TO BE ABLE TO USE SYRIAN PORTS TO EXPORT WHEAT TO SYRIA, NEIGHBORING COUNTRIES - ROGOZIN
RUSSIAN MILITARY SUCCESS IN SYRIA SHOULD BE SUPPORTED BY LONG-TERM ORIENTATION OF SYRIA TOWARD RUSSIA, RUSSIAN MARKET - ROGOZIN
SYRIA SUFFERS $400 BLN DAMAGE FROM WAR CONTINUING SEVERAL YEARS - ROGOZIN CITING ASSAD